TCRX - TScan Therapeutics Announces Updates to its Board of Directors | Benzinga
Garry A. Nicholson, an experienced executive with regulatory and commercial expertise, joins the Board of Directors
Timothy Barberich retires as Chair; Stephen Biggar, M.D., Ph.D. assumes the role of Chair
WALTHAM, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced changes to its Board of Directors. Garry A. Nicholson has been appointed to the Company's Board of Directors. In addition, Timothy Barberich has retired as a Member and Chair of the Board of Directors. Current board member Stephen Biggar, M.D., Ph.D., will assume the role of Chair of the Board of Directors.
"We are pleased to welcome Garry to our Board of Directors. He has a breadth of experience in oncology development and commercialization spanning more than 35 years, including serving as president of Pfizer Oncology where he led its global oncology franchise," said Gavin MacBeath, Ph.D., Chief Executive Officer. "Garry has extensive expertise in operations, sales, regulatory strategy, and commercialization, and we look forward to working with him as we advance our clinical programs toward pivotal studies."
"I am delighted to be joining TScan's Board and look forward to working with the leadership team to further advance the progress of this company and its mission of bringing life-changing therapies to patients suffering from cancer. My previous experience across commercialization, operations, regulatory affairs and launch strategy will help support the growth of TScan and the advancement of this innovative pipeline," said Mr. Nicholson.
"We all wish Tim well as he retires from the Board. He has been an esteemed member of the Board since 2019 and as Chair of the Board since 2021. TScan has benefitted from Tim's more than 40 years' experience in pharmaceutical and medical device companies, and we appreciate his contributions and insights that have helped us grow from a discovery-stage organization into a clinically focused company since our inception," added Dr. MacBeath. "Steve has served on the Board of TScan ...